Clinical Trial

A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and toxicity of irinotecan with dabrafenib, cetuximab/panitumumab in the second line of treatment for the potential treatment of colorectal cancer that: has a metastatic, inoperable; has a mutation in the BRAF gene. Participants in this study will receive one of the following study treatments: These participants will receive in the second line is irinotecan, dabrafenib + trametinib, cetuximab or panitumumab. This trial is currently enrolling participants who will receive either irinotecan and dabrafenib plus cetuximab or panitumumab in the second line of therapy. The study team will monitor how each participant responds to the study treatment for up to about 3 years.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-05-03.
Trial Details
NCT Number NCT06967155
Lead Sponsor Blokhin's Russian Cancer Research Center
Collaborators: City Clinical Oncology Hospital No 1, Moscow City Oncology Hospital No. 62, The Loginov MCSC MHD, Moscow Multidisciplinary Clinical Center "Kommunarka"
Conditions Neoplasms
Enrollment 23 participants
Start Date 2025-03-01
Primary Completion 2027-11-10 (estimated)
Study Completion 2028-06-10 (estimated)
Updated on ClinicalTrials.gov 2025-10-02